Praxis Precision Medicines (PRAX) Q2 2026 earnings summary

Executive summary

• Transitioned from a development-stage to a commercial-stage organization, with two NDAs (ulixacaltamide for essential tremor and relutrigine for SCN2A/SCN8A DEE) in late-stage FDA review, no major safety or efficacy concerns, and expected approvals within six months.

• Commercial infrastructure, including leadership, field force, and distribution, is in place for both launches, with inventory being built and patient support programs established.

• Received third Breakthrough Therapy Designation for elsunersen following positive EMBRAVE Part A trial results for SCN2A DEE.

• Ongoing clinical programs for vormatrigine and multiple preclinical ASO candidates; commercial preparations underway for potential product launches.

• Cash and investments totaled $1.4 billion as of June 30, 2026, providing operational runway into 2028.

Financial highlights

• Q2 2026 operating expenses were $96.9 million, up from $76 million in Q2 2025, driven by increased R&D ($69.4 million) and G&A ($27.5 million) spending.

• Net loss was $83.7 million for Q2 2026, compared to $71.1 million in Q2 2025.

• Cash, cash equivalents, and marketable securities totaled $1.4 billion as of June 30, 2026, up from $926 million at year-end 2025, mainly due to public offerings and interest income.

• Operating cash outflow was $78 million in Q2 2026, compared to $55 million in Q2 2025.

• Other income rose to $13.2 million in Q2 2026, primarily from interest income.

Outlook and guidance

• Both ulixacaltamide and relutrigine launches are expected within six months, with commercial teams fully hired and launch readiness ahead of PDUFA dates.

• Cash position expected to fund operations into 2028, supporting ongoing R&D, clinical trials, and commercialization activities.

• G&A expenses expected to increase in the second half of 2026 to support launches, including expanded commercial field teams and disease awareness campaigns.

• Topline results from EMERALD (relutrigine) and EMBRAVE3 (elsunersen) studies expected in late 2026 and 2027.

• POWER2 and POWER3 studies for vormatrigine planned to initiate in Q4 2026.